title: Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis.
abstract: Placebo and pharmacodynamic (PD) models were developed which link temporal measures of efficacy in children with attention deficit hyperactivity disorder (ADHD) and methylphenidate (MPH) plasma concentrations from adults. These models can be used to predict daily pediatric clinical measure profiles following administration of different MPH formulations in children without conducting pediatric pharmacokinetic (PK) or PD studies by using more easily obtained adult PK data. Mean PK data from various extended-release MPH formulations studied in adults and mean PD data from nine pediatric efficacy studies were obtained from the literature. The individual time-course of the clinical measures from three pediatric trials were also analyzed after being combined with the meta-analysis data. The clinical measure profiles following placebo administration were described by indirect response models with time-varying elimination rates. MPH pharmacodynamic effect was described by E(max) models, which included time-dependent tolerance. Internal and external evaluations using a visual predictive check technique confirmed the prediction capability of the models. This modeling exercise demonstrated that time courses of MPH concentrations in adults with different drug release patterns can be used to predict time courses of clinical efficacy parameters in pediatrics by employing the models developed by meta-analysis.
authors.affiliation: Advanced Modeling & Simulation, Janssen Research & Development, LLC, 920 Route 202, Raritan, NJ 08869, USA. HKimko@its.jnj.com
authors.forename: Holly
authors.initials: H
authors.lastname: Kimko
authors.forename: Ekaterina
authors.initials: E
authors.lastname: Gibiansky
authors.forename: Leonid
authors.initials: L
authors.lastname: Gibiansky
authors.forename: H Lynn
authors.initials: HL
authors.lastname: Starr
authors.forename: Joris
authors.initials: J
authors.lastname: Berwaerts
authors.forename: Joseph
authors.initials: J
authors.lastname: Massarella
authors.forename: Frank
authors.initials: F
authors.lastname: Wiegand
mesh_terms: D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000378:metabolism*; D002648:Child; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008954:Models, Biological; D016032:Randomized Controlled Trials as Topic / Q000379:methods
chemical_list: D003692:Delayed-Action Preparations; D008774:Methylphenidate